Several studies have indicated a relation between the development of RVO and elevated intraocular pressure (IOP) and glaucoma \[9\]. Further investigations into the structural alterations in the fellow eyes of individuals with unilateral RVO have revealed that the pRNFL is thinner than in healthy eyes, suggesting that there may be systemic risk factors for both RVO and glaucoma
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Aflibercept is a medication used to treat and manage neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, macular edema associated with retinal vein occlusion, and diabetic retinopathy. It is in the vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) antagonist class of medications. Aflibercept acts as a soluble protein decoy for VEGF receptors to inhibit the predominant signaling pathway responsible for angiogenesis and vascular leakage. Aflibercept and other anti-VEGF inhibitors have become the gold standard in controlling neovascular (wet) age-related macular degeneration (NVAMD). T
Akram Fekry Elgazzar
Damietta, Egypt
peri-papillary retinal nerve fiber layer thickness
Layer of the retina. The thickness was measured by Optical Coherence Tomography
Time frame: Base line
peri-papillary retinal nerve fiber layer thickness
Layer of the retina. The thickness was measured by Optical Coherence Tomography
Time frame: 6 months post injection
peri-papillary retinal nerve fiber layer thickness
Layer of the retina. The thickness was measured by Optical Coherence Tomography
Time frame: 12 months post injection
peri-papillary retinal nerve fiber layer thickness
Layer of the retina. The thickness was measured by Optical Coherence Tomography
Time frame: 24 months post injection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.